Sanovask^® Magnesium (Tablets) Instructions for Use

Marketing Authorization Holder

Avexima JSC (Russia)

Manufactured By

Irbit Chemical Pharmaceutical Plant, JSC (Russia)

Or

Avexima Siberia LLC (Russia)

ATC Code

B01AC30 (Platelet aggregation inhibitors in combination)

Active Substances

Magnesium hydroxide (Ph.Eur.)

Acetylsalicylic acid (Ph.Eur.)

Dosage Form

Sanovask® Magnesium

Film-coated tablets 150 mg+30.39 mg: 30 or 100 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets white or almost white, round, biconvex; the core on the cross-section is white or almost white.

Excipients: microcrystalline cellulose 101, corn starch, potato starch, magnesium stearate.

Film coating composition: hypromellose, macrogol 4000, talc.

10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – polyethylene jars (1) – cardboard packs.

Clinical-Pharmacological Group

Antiplatelet agent

Pharmacotherapeutic Group

Antithrombotic agents; antiplatelet agents, other than heparin

Pharmacological Action

NSAID, antiplatelet agent.

The mechanism of action of acetylsalicylic acid is based on the irreversible inhibition of the COX-1 enzyme, resulting in blocked synthesis of thromboxane A₂ and suppressed platelet aggregation. It is believed that Acetylsalicylic acid has other mechanisms for suppressing platelet aggregation, which expands its scope of application in various vascular diseases. Acetylsalicylic acid also has anti-inflammatory, analgesic, and antipyretic effects.

Magnesium hydroxide protects the gastrointestinal mucosa from the effects of acetylsalicylic acid.

Pharmacokinetics

After oral administration of the drug, Acetylsalicylic acid is rapidly and almost completely absorbed from the gastrointestinal tract. Food intake slows down absorption. Acetylsalicylic acid is partially metabolized during absorption. The bioavailability of acetylsalicylic acid is about 70%, but this value is characterized by significant individual variability due to presystemic hydrolysis in the gastrointestinal mucosa and in the liver with the formation of salicylic acid under the action of enzymes. The bioavailability of salicylic acid is 80-100%.

C_max of acetylsalicylic acid in blood plasma is reached within 10-20 minutes after oral administration, of salicylic acid – within 0.3-2 hours. Acetylsalicylic acid and salicylic acid are highly bound to plasma proteins and are rapidly distributed in the body. The degree of binding of salicylic acid to plasma proteins is concentration-dependent, non-linear. At low concentrations (<100 µg/ml), up to 90% of salicylic acid is bound to plasma proteins, at high concentrations (>400 µg/ml) – up to 75%. Salicylic acid crosses the placental barrier and is found in breast milk.

Salicylic acid is metabolized under the influence of enzymes, mainly in the liver, forming metabolites (phenyl salicylate, salicyl glucuronide, and salicyluric acid) found in many tissues and body fluids. In women, the metabolic process is slower (lower serum enzyme activity).

Acetylsalicylic acid and its metabolites are excreted primarily by the kidneys. T_1/2 of acetylsalicylic acid from blood plasma is 15-20 minutes, of salicylic acid – 2-3 hours when taking acetylsalicylic acid in low doses and increases significantly when taking acetylsalicylic acid in high doses due to saturation of enzyme systems. Unlike other salicylates, with repeated administration of the drug, non-hydrolyzed Acetylsalicylic acid does not accumulate in the blood serum. In patients with normal renal function, 80-100% of a single dose of acetylsalicylic acid is excreted by the kidneys within 24-72 hours.

In renal failure, during pregnancy, and in newborns, salicylates can displace bilirubin from its binding to albumin and contribute to the development of bilirubin encephalopathy.

Magnesium hydroxide in the applied doses does not affect the bioavailability of acetylsalicylic acid.

Indications

Primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure in the presence of risk factors (e.g., diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age); prevention of recurrent myocardial infarction and thrombosis of blood vessels; prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty); unstable angina.

ICD codes

Dosage Regimen

Take orally once daily with a full glass of water.

Administer 1-2 hours after a meal to minimize potential gastrointestinal discomfort.

Swallow the tablet whole; do not crush, chew, or break it.

This medication is intended for long-term, continuous use to maintain its antiplatelet effect.

The duration of therapy is determined by the physician based on the individual’s medical condition and risk factors.

If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose; in that case, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to catch up.

No specific dosage adjustment is required for initial administration or upon discontinuation of therapy.

Adhere strictly to the prescribed regimen; do not alter the dose or frequency without consulting a physician.

Adverse Reactions

In general, preparations containing this combination are well tolerated.

Nervous system disorders: frequent – headache, insomnia; infrequent – dizziness, drowsiness; rare – tinnitus, intracerebral hemorrhage.

Blood and lymphatic system disorders: very frequent – increased bleeding; rare – anemia; very rare – aplastic anemia, hypoprothrombinemia, thrombocytopenia, neutropenia, leukopenia, eosinophilia, agranulocytosis. There are reports of cases of hemolysis and hemolytic anemia in patients with severe forms of glucose-6-phosphate dehydrogenase deficiency.

Respiratory system disorders: frequent – bronchospasm.

Gastrointestinal disorders: very frequent – heartburn; frequent – nausea, vomiting; infrequent – abdominal pain, gastric and duodenal ulcers, gastrointestinal bleeding; rare – perforation of gastric or duodenal ulcer, increased activity of liver enzymes; very rare – stomatitis, esophagitis, erosive lesions of the upper gastrointestinal tract (including with strictures), colitis, irritable bowel syndrome.

Allergic reactions: infrequent – urticaria, angioedema, skin rash, skin itching, rhinitis, nasal mucosa swelling; very rare – anaphylactic shock, cardiorespiratory distress syndrome.

Other: very rare – impaired renal function.

Contraindications

Hypersensitivity to acetylsalicylic acid, any of the excipients of the drug, other NSAIDs; bronchial asthma induced by the intake of salicylates and NSAIDs; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs; erosive and ulcerative lesions of the gastrointestinal tract in the acute phase; gastrointestinal bleeding; cerebral hemorrhage; tendency to bleeding (thrombocytopenia, hemorrhagic diathesis, vitamin K deficiency); severe renal failure (creatinine clearance less than 30 ml/min); severe hepatic failure (more than 9 points on the Child-Pugh scale); I and III trimesters of pregnancy; lactation period; glucose-6-phosphate dehydrogenase deficiency; simultaneous use with methotrexate (at a dose of ≥15 mg per week); age under 18 years (efficacy and safety not established).

With caution

Gout, hyperuricemia; history of peptic ulcer disease or gastrointestinal bleeding; mild to moderate renal failure (creatinine clearance more than 30 ml/min) and/or hepatic failure (9 points or less on the Child-Pugh scale); bronchial asthma; chronic respiratory diseases; hay fever; polyposis of the nose and paranasal sinuses; allergic conditions; period before surgery; simultaneous use with certain medications (including methotrexate at a dose of <15 mg per week, valproic acid, anticoagulants, thrombolytic and antiplatelet agents, NSAIDs and acetylsalicylic acid derivatives in high doses, narcotic analgesics, sulfonamides /including co-trimoxazole/, carbonic anhydrase inhibitors /acetazolamide/, digoxin, lithium, oral hypoglycemic agents /sulfonylurea derivatives/, insulin, selective serotonin reuptake inhibitors, ibuprofen, systemic corticosteroids); concomitant use with ethanol (ethanol-containing preparations, alcoholic beverages); II trimester of pregnancy.

Use in Pregnancy and Lactation

The use of salicylates in high doses in the first trimester of pregnancy is associated with an increased incidence of fetal developmental defects (cleft palate, heart defects). Use in the first trimester of pregnancy is contraindicated. In the second trimester of pregnancy, it can be prescribed only after a strict assessment of the benefit of treatment for the mother versus the potential risk to the fetus, in doses not exceeding 150 mg/day for a short period of time. In the third trimester of pregnancy, salicylates in high doses (more than 300 mg/day) cause inhibition of labor, premature closure of the fetal arterial duct, increased bleeding in the mother and fetus, and use immediately before delivery can cause intracranial hemorrhage, especially in premature infants. Use in the third trimester of pregnancy is contraindicated.

Salicylates and their metabolites pass into breast milk in small amounts. Clinical data to assess the safety of acetylsalicylic acid use during breastfeeding are insufficient. Before prescribing acetylsalicylic acid during lactation, the expected benefit of therapy for the mother and the potential risk for breastfed infants should be assessed. Accidental intake of salicylates during lactation is not accompanied by the development of adverse reactions in the child and does not require discontinuation of breastfeeding. However, if long-term use of this combination is necessary, breastfeeding should be discontinued immediately.

Use in Hepatic Impairment

Contraindicated in severe hepatic impairment (more than 9 points on the Child-Pugh scale).

The drug should be prescribed with caution in hepatic impairment (9 points or less on the Child-Pugh scale).

Use in Renal Impairment

Contraindicated in severe renal impairment (creatinine clearance less than 30 ml/min).

The drug should be prescribed with caution in mild to moderate renal impairment (creatinine clearance more than 30 ml/min).

Pediatric Use

Contraindicated in children under 18 years of age (efficacy and safety not established).

Geriatric Use

Long-term use of acetylsalicylic acid in low doses by elderly patients is associated with an increased risk of gastrointestinal bleeding.

Special Precautions

Acetylsalicylic acid can provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, polyposis of the nose and paranasal sinuses, chronic respiratory diseases, as well as allergic reactions (e.g., skin reactions, itching, urticaria) to other drugs.

The inhibitory effect of acetylsalicylic acid on platelet aggregation persists for several days after administration, which should be considered during and after surgery. Several days before planned surgery, the risk of bleeding should be assessed against the risk of ischemic complications in patients taking low-dose acetylsalicylic acid. If there is a significant risk of bleeding, the drug should be temporarily discontinued.

In case of impaired renal function (creatinine clearance more than 30 ml/min), as well as in circulatory disorders due to atherosclerosis of the renal arteries, chronic heart failure, extensive surgery, sepsis, cases of massive bleeding, caution should be exercised, since in all these cases ASA may increase the risk of acute renal failure/worsening of renal function. It is known that the risk of acute renal failure increases with the combined use of other NSAIDs with ACE inhibitors or diuretics. Monitoring of renal function is recommended.

In patients with mild to moderate hepatic impairment, liver function should be monitored regularly.

During the first weeks of concomitant use of the drug and methotrexate at a dose of less than 15 mg per week, a blood test should be performed weekly. Careful monitoring is necessary even with minor renal impairment, as well as in elderly patients.

When acetylsalicylic acid is used concomitantly with anticoagulants, thrombolytics, and antiplatelet drugs, the risk of bleeding and damaging effects on the gastrointestinal mucosa increases, so bleeding time should be monitored.

Concomitant use with ibuprofen is not recommended in patients with an increased risk of cardiovascular diseases, since a decrease in the antiplatelet effect of acetylsalicylic acid in doses up to 300 mg leads to a decrease in cardioprotective effects. Patients taking ibuprofen for pain relief should inform their doctor.

Monitoring of plasma concentrations of digoxin and lithium is recommended at the beginning or end of concomitant use with the Acetylsalicylic acid+Magnesium hydroxide combination; dose adjustment may be required.

When systemic corticosteroids and acetylsalicylic acid are used concomitantly, the plasma concentration of salicylates decreases, and after discontinuation of systemic corticosteroids, an overdose of salicylates is possible. Furthermore, concomitant use increases the risk of damage to the gastrointestinal mucosa and bleeding.

The use of acetylsalicylic acid in doses exceeding the recommended therapeutic doses (by patients of any age), or long-term use of acetylsalicylic acid in low doses (by elderly patients) is associated with an increased risk of gastrointestinal bleeding. With long-term use, a complete blood count and stool occult blood test, as well as liver functional state, should be periodically monitored.

Acetylsalicylic acid in low doses reduces the excretion of uric acid and can provoke the development of gout in predisposed patients with reduced uric acid excretion.

Acetylsalicylic acid in high doses has a hypoglycemic effect, which should be considered in patients with diabetes mellitus receiving oral hypoglycemic agents or insulin.

In severe forms of glucose-6-phosphate dehydrogenase deficiency, Acetylsalicylic acid can cause hemolysis and hemolytic anemia. Factors that increase the risk of hemolysis and hemolytic anemia are fever, acute infections, and high doses of acetylsalicylic acid.

Effect on ability to drive vehicles and operate machinery

During the treatment period, caution must be exercised when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

When used concomitantly, Acetylsalicylic acid enhances the effect and increases the risk of toxicity of the following drugs

• methotrexate (due to reduced renal clearance and displacement from plasma protein binding);
• valproic acid (due to displacement from plasma protein binding).

Acetylsalicylic acid enhances the effect and increases the risk of adverse reactions of the following drugs

• narcotic analgesics, other NSAIDs (due to synergy of action);
• oral hypoglycemic agents (sulfonylurea derivatives) and insulin (due to the hypoglycemic properties of acetylsalicylic acid itself in high doses (more than 2 g/day) and displacement of sulfonylurea derivatives from plasma protein binding);
• thrombolytic drugs, heparin, indirect anticoagulants (including ticlopidine, warfarin), antiplatelet agents (including clopidogrel, dipyridamole) due to synergy of the main therapeutic effects and displacement from plasma protein binding;
• sulfonamides (including co-trimoxazole) due to displacement from plasma protein binding and increased plasma concentration;
• carbonic anhydrase inhibitors (acetazolamide). Concomitant use with acetylsalicylic acid may lead to the development of severe acidosis and increased toxic effects on the central nervous system;
• digoxin and lithium – due to reduced renal excretion of digoxin and lithium with an increase in their plasma concentration;
• selective serotonin reuptake inhibitors (including sertraline, paroxetine) – due to synergy of action (with an increased risk of bleeding from the upper gastrointestinal tract).
• ethanol (alcohol and ethanol-containing preparations) – with increased damaging effect on the gastrointestinal mucosa and increased risk of gastrointestinal bleeding.

Reduce the antiplatelet effect of acetylsalicylic acid

• ibuprofen (due to antagonism regarding the suppression of platelet aggregation);
• systemic corticosteroids (enhance the elimination of salicylates);
• antacids containing magnesium and/or aluminum hydroxide, cholestyramine (reduce the absorption of acetylsalicylic acid from the gastrointestinal tract).

Acetylsalicylic acid in low doses weakens the effect of uricosuric drugs (benzbromarone, probenecid, sulfinpyrazone) due to competitive suppression of renal tubular excretion of uric acid.

Acetylsalicylic acid in high doses, like other NSAIDs, may reduce the antihypertensive effect of diuretics (due to a decrease in the glomerular filtration rate caused by the suppression of renal prostaglandin synthesis) and antihypertensive agents. In particular, due to competitive blockade of prostacyclin synthesis, the effectiveness of ACE inhibitors may be reduced.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.